Sleep Quality in Mechanically Ventilated Patients
This study has been completed.
Sponsor:
Lawson Health Research Institute
Collaborators:
Ontario Lung Association
Covidien
Information provided by (Responsible Party):
Karen Bosma, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT01410149
First received: August 3, 2011
Last updated: August 13, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients requiring mechanical ventilation in the ICU will undergo three consecutive nights of polysomnography to record sleep patterns while receiving three modes of mechanical ventilation; Proportional assist ventilation (PAV), Pressure support ventilation (PSV), Assist control ventilation (ACV), applied in random order. The purpose is to determine the effect of mode of mechanical ventilation on patient-ventilator asynchrony and sleep quality.
| Condition | Intervention |
|---|---|
|
Respiratory Failure |
Other: PAV Other: PSV Other: ACV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | The Influence of Mode and Patient-ventilator Interaction on Sleep Quality in the ICU |
Resource links provided by NLM:
Further study details as provided by Lawson Health Research Institute:
Primary Outcome Measures:
- Sleep quality [ Time Frame: 3 nights ] [ Designated as safety issue: No ]Sleep fragmentation (number of arousals and awakenings/hr sleep), sleep architecture (% time asleep spent in Stage 1, 2, 3/4 and REM sleep)
Secondary Outcome Measures:
- Patient-ventilator asynchrony [ Time Frame: 3 nights ] [ Designated as safety issue: No ]Incidence of patient-ventilator asynchrony (asynchrony index, % of asynchronous breaths per minute)
Other Outcome Measures:
- Delirium [ Time Frame: 3 days ] [ Designated as safety issue: No ]Positive score on a delirium screening tool (CAM-ICU or ICDSC)
- Comfort [ Time Frame: 3 days ] [ Designated as safety issue: No ]Patient's assessment of their own breathing comfort and their perceived quality of sleep, indicated on a visual analogue scale
- Respiratory pattern [ Time Frame: 3 nights ] [ Designated as safety issue: No ]Measurement of average tidal volume, respiratory rate, minute ventilation and non-invasive measurement of respiratory muscle effort relative to maximum effort
- Blood gas [ Time Frame: evening and morning ] [ Designated as safety issue: No ]measurement of paO2 and paCO2
| Enrollment: | 13 |
| Study Start Date: | April 2007 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: PAV
Proportional Assist Ventilation (PAV+ on PB840 ventilator)
|
Other: PAV
Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
|
|
Active Comparator: PSV
Pressure Support Ventilation (PSV on PB840 ventilator)
|
Other: PSV
Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
|
|
Active Comparator: ACV
Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
|
Other: ACV
Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18-75
- received mechanical ventilation >72 hours
- glasgow coma scale >10
- acute physiology score <13
- ready for partial ventilatory support: intact respiratory drive, PaO2/FiO2 ratio >200 on positive end expiratory pressure (PEEP) less than or equal to 5 cmH2O, and PH of 7.35 to 7.45
- sedation: analgesia at dose not higher than 0.01 mg/kg/hr morphine equivalent x 48 hours, sedation at dose not higher than 0.01 mg/kg/hr lorazepam equivalent x 72 hours.
- anticipate ongoing need for partial ventilatory support for the following 72 hours
Exclusion Criteria:
- Successful completion of spontaneous breathing trial
- Neurological injury, encephalopathy or abnormal EEG
- History of central sleep apnea
- General anaesthesia within 72 hours from study entry
- Requiring haloperidol >10 mg/24 hours
- hemodynamically unstable
- sepsis
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01410149
Locations
| Canada, Ontario | |
| London Health Sciences Centre - University Hospital | |
| London, Ontario, Canada, N6A 5A5 | |
Sponsors and Collaborators
Lawson Health Research Institute
Ontario Lung Association
Covidien
Investigators
| Principal Investigator: | Karen J. Bosma, MD, FRCPC | Lawson Health Research Institute |
More Information
Publications:
| Responsible Party: | Karen Bosma, Principal Investigator, Lawson Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT01410149 History of Changes |
| Other Study ID Numbers: | R-07-106, 13114 |
| Study First Received: | August 3, 2011 |
| Last Updated: | August 13, 2012 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Lawson Health Research Institute:
|
PAV (proportional assist ventilation); sleep; polysomnography; mechanical ventilation |
Additional relevant MeSH terms:
|
Respiratory Insufficiency Respiration Disorders Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 23, 2013